Back to News
Market Impact: 0.2
Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
Innate Pharma's average one-year analyst price target was raised 27.91% to $8.22 per share from $6.43 on September 13, 2026. The upward revision signals improved analyst expectations for the biotech company, though the article provides no operating, clinical, or financial catalyst behind the change.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
IPHA0.48
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why AMD Stock Jumped 30% in September
- Nike falls to 13-year low. Why analysts don't think the selling is over yet